- Home
- ISPR vs SLN Comparison
ISPR vs SLN Comparison
Compare ISPR & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISPR
- SLN
- Stock Information
- Founded
- ISPR 2019
- SLN 1994
- Country
- ISPR United States
- SLN United Kingdom
- Employees
- ISPR N/A
- SLN N/A
- Industry
- ISPR Medicinal Chemicals and Botanical Products
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- ISPR Health Care
- SLN Health Care
- Exchange
- ISPR Nasdaq
- SLN Nasdaq
- Market Cap
- ISPR 152.0M
- SLN 281.0M
- IPO Year
- ISPR 2023
- SLN N/A
- Fundamental
- Price
- ISPR $2.56
- SLN $5.92
- Analyst Decision
- ISPR Strong Buy
- SLN Buy
- Analyst Count
- ISPR 2
- SLN 5
- Target Price
- ISPR $10.00
- SLN $32.60
- AVG Volume (30 Days)
- ISPR 75.5K
- SLN 120.4K
- Earning Date
- ISPR 05-12-2025
- SLN 08-14-2025
- Dividend Yield
- ISPR N/A
- SLN N/A
- EPS Growth
- ISPR N/A
- SLN N/A
- EPS
- ISPR N/A
- SLN N/A
- Revenue
- ISPR $144,700,345.00
- SLN $27,701,000.00
- Revenue This Year
- ISPR N/A
- SLN N/A
- Revenue Next Year
- ISPR $35.39
- SLN N/A
- P/E Ratio
- ISPR N/A
- SLN N/A
- Revenue Growth
- ISPR N/A
- SLN N/A
- 52 Week Low
- ISPR $2.09
- SLN $1.97
- 52 Week High
- ISPR $8.13
- SLN $22.47
- Technical
- Relative Strength Index (RSI)
- ISPR 50.95
- SLN 58.20
- Support Level
- ISPR $2.09
- SLN $5.06
- Resistance Level
- ISPR $2.56
- SLN $6.25
- Average True Range (ATR)
- ISPR 0.22
- SLN 0.48
- MACD
- ISPR 0.00
- SLN -0.03
- Stochastic Oscillator
- ISPR 61.84
- SLN 63.20
About ISPR Ispire Technology Inc.
Ispire Technology Inc is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The company sells its cannabis vaping in the United States, Europe, Canada, and South Africa.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.